In phase I studies, vanucizumab has been associated with marked post-infusion reductions in circulating unbound VEGF-A and Ang-2 in plasma, tumour and wound-healing biopsies, thus confirming its mechanism of action (21). The gene discussed is ANGPT2; the disease is neoplasm.